Examining the interaction of apo E and neurotoxicity on a murine model of ALS-PDC.
Epidemiological studies have shown a positive relationship between cycad flour consumption and the development of the neurodegenerative disorder, amyotrophic lateral sclerosis - parkinsonism - dementia complex (ALS-PDC). Apolipoprotein E (apo E) allele variations have been associated with genetic susceptibility in neurodegenerative diseases, including ALS-PDC. We have studied cycad toxicity in a mouse model of ALS-PDC with a particular interest in its impact on the central nervous system (CNS) in both apo E knock-out (KO) mice and their wild-type (WT) counterparts. Behavioral motor tests, motor neuron counts, and immunohistochemical staining in brain and spinal cord, as well as routine histological examinations on internal organs, were performed to evaluate cycad toxicity. Plasma cholesterol levels were also measured before and during the study. Cycad treatment was associated with higher levels of plasma cholesterol only in apo E KO mice; increased levels of plasma cholesterol did not result in increased athero genesis. Cycad-fed wild-type mice developed progressive behavioral deficits including ALS-PDC-like pathological outcomes, while cycad-fed apo E KO mice were not significantly affected. Cycad-fed wild-type mice had shorter gait length measurements along with higher active caspase-3 levels in the striatum, substantia nigra, primary motor cortex, and spinal cord as compared with corresponding controls. These changes were associated with decreased labeling for glutamate transporter 1B and tyrosine hydroxylase activity levels. No evidence of cycad toxicity was observed in internal organs of either wild-type or apo E KO mice. Our data demonstrate that apo E KO mice are less susceptible to cycad toxicity, suggesting a role for apo E as a possible genetic susceptibility factor for some forms of toxin-induced neurodegeneration.
Wilson
J M B
JM
Department of Opthalmology and Program in Neuroscience, University of British Columbia, Vancouver, Canada.
Petrik
M S
MS
Moghadasian
M H
MH
Shaw
C A
CA
D027322:Amino Acid Transport System X-AG / Q000378:metabolism; D000690:Amyotrophic Lateral Sclerosis / Q000209:etiology* / Q000378:metabolism / Q000503:physiopathology; D000818:Animals; D001057:Apolipoproteins E / Q000235:genetics*; D017209:Apoptosis; D001522:Behavior, Animal; D001921:Brain / Q000473:pathology; D053148:Caspase 3; D020169:Caspases / Q000378:metabolism; D002452:Cell Count; D002784:Cholesterol / Q000097:blood; D029784:Cycas / Q000009:adverse effects*; D003704:Dementia / Q000209:etiology* / Q000378:metabolism / Q000503:physiopathology; D004195:Disease Models, Animal; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009046:Motor Neurons / Q000473:pathology; D020734:Parkinsonian Disorders / Q000209:etiology* / Q000378:metabolism / Q000503:physiopathology; D013116:Spinal Cord / Q000473:pathology; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D027322:Amino Acid Transport System X-AG; D001057:Apolipoproteins E; D002784:Cholesterol; D014446:Tyrosine 3-Monooxygenase; C505409:Casp3 protein, mouse; D053148:Caspase 3; D020169:Caspases